To Örebro University

oru.seÖrebro University Publications
Planned maintenance
A system upgrade is planned for 17/11-2026, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
Link to record
Permanent link

Direct link
Publications (10 of 41) Show all publications
Athlin, S., Steger, N., Thazhath Veettil, J., Gentile, C., Demirel, I., Sirsjö, A., . . . Paramel Varghese, G. (2026). Cardiac spheroids as a human model for inflammation induced cardiac dysfunction. Biofabrication, 18(2), Article ID 025007.
Open this publication in new window or tab >>Cardiac spheroids as a human model for inflammation induced cardiac dysfunction
Show others...
2026 (English)In: Biofabrication, ISSN 1758-5082, E-ISSN 1758-5090, Vol. 18, no 2, article id 025007Article in journal (Refereed) Published
Abstract [en]

Inflammatory signaling is a major contributor to cardiac dysfunction in diseases such as sepsis, myocarditis, and heart failure, yet existing in vitro models lack the multicellular complexity and physiological relevance needed to accurately recapitulate human cardiac pathology. In this study, we used human cardiac spheroids, three dimensional microtissues composed of cardiomyocytes, fibroblasts, and endothelial cells to study lipopolysaccharide induced inflammation. High resolution confocal microscopy confirmed a radial distribution of cell types within the spheroids. Following 24 h LPS stimulation, the spheroids exhibited no significant increase in lactate dehydrogenase release, indicating preserved membrane integrity and absence of overt cytotoxicity. Nevertheless, a robust inflammatory response was observed at both transcriptional and protein levels, including significant upregulation and secretion of TLR2, IL6, TNF, CXCL8, and CCL2. Mitochondrial stress testing revealed significantly reduced basal respiration, ATP production, and maximal respiratory capacity. Functional analyses showed impaired contractility characterized by reduced beat rate, delayed time to peak contraction, and prolonged relaxation time. Together, these findings demonstrate that human cardiac spheroids mount a physiologically relevant, multicellular inflammatory response that compromises both mitochondrial metabolism and mechanical performance. The model offers a powerful platform for investigating innate immune activation and for screening therapeutic interventions targeting inflammation induced cardiac dysfunction.

Place, publisher, year, edition, pages
Institute of Physics Publishing (IOPP), 2026
Keywords
cardiac dysfunction, cardiac spheroids, contractility, cytokines, inflammation, lipopolysaccharide (LPS), mitochondrial respiration
National Category
Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:oru:diva-127637 (URN)10.1088/1758-5090/ae4ad7 (DOI)001711717100001 ()41747295 (PubMedID)
Funder
Knowledge Foundation, 20220014Örebro University, 2023-01-31
Available from: 2026-02-27 Created: 2026-02-27 Last updated: 2026-03-20Bibliographically approved
Steger, N., Isaksson, E., Nordenskjöld, A. M. & Athlin, S. (2026). Factors associated with antibiotic initiation and bacterial coinfection in adults with confirmed influenza. BMC Infectious Diseases, 26(1), Article ID 742.
Open this publication in new window or tab >>Factors associated with antibiotic initiation and bacterial coinfection in adults with confirmed influenza
2026 (English)In: BMC Infectious Diseases, E-ISSN 1471-2334, Vol. 26, no 1, article id 742Article in journal (Refereed) Published
Abstract [en]

Background: Influenza causes seasonal epidemics worldwide. Bacterial coinfection is a serious complication that, due to diagnostic uncertainty, often results in empirical antibiotic overuse. We aimed to identify clinical and biochemical factors associated with antibiotic initiation and bacterial coinfection in adults with confirmed influenza at the emergency department.

Methods: Adult patients presenting to the emergency department with laboratory-confirmed influenza were included across three influenza seasons (2017-2020). Clinical and biochemical data were collected through medical chart review.

Results: A total of 174 influenza-positive patients were included. Independent predictors of antibiotic initiation were clinical scores NEWS2 >= 7 (aOR 8.99, 95% CI 2.38-33.96) and CRB-65 >= 2 (aOR 13.22, 95% CI 2.70-64.73), as well as biomarkers CRP (aOR 1.57, 95% CI 1.21-2.02), and white blood cell count (aOR 1.25, 95% CI 1.07-1.46). Only CRP was independently associated with bacterial coinfection (aOR 1.47, 95% CI 1.16-1.86). A CRP threshold >= 20 mg/L demonstrated 100% sensitivity for detecting bacterial coinfection.

Conclusion: NEWS2, CRB-65, CRP, and white blood cell count were independently associated with antibiotic initiation in adults with influenza, while only CRP predicted bacterial coinfection. Our findings could improve antibiotic stewardship strategies by underscoring the limited predictive value of clinical scores and the optimal use of biomarkers.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2026
Keywords
Antibiotics, Bacterial coinfection, Emergency department, Influenza
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-128235 (URN)10.1186/s12879-026-13166-0 (DOI)001737458900001 ()41877014 (PubMedID)
Funder
Örebro UniversityNyckelfondenRegion Örebro County
Available from: 2026-04-01 Created: 2026-04-01 Last updated: 2026-04-29Bibliographically approved
Alpkvist, H., Athlin, S., Norrby-Teglund, A. & Stralin, K. (2025). Diagnostic and prognostic potential of plasma and sputum thrombomodulin in bacterial community-acquired pneumonia. Infectious Diseases, 57(11), 1078-1087
Open this publication in new window or tab >>Diagnostic and prognostic potential of plasma and sputum thrombomodulin in bacterial community-acquired pneumonia
2025 (English)In: Infectious Diseases, ISSN 2374-4235, E-ISSN 2374-4243, Vol. 57, no 11, p. 1078-1087Article in journal (Refereed) Published
Abstract [en]

Background: Soluble thrombomodulin, a marker of endothelial cell injury, is released into the circulation during endothelial damage and has been observed at elevated concentrations in bacterial infections. This study aimed to investigate the correlation of thrombomodulin concentrations in plasma and sputum with disease severity and etiology in bacterial community-acquired pneumonia (CAP).

Methods: A prospective study was conducted on adults hospitalized with radiologically confirmed bacterial CAP. Plasma and sputum samples were collected upon admission, and thrombomodulin concentrations were quantified using an enzyme-linked immunosorbent assay. The study included a multivariate analysis to assess whether thrombomodulin concentrations were associated with disease severity and/or bacterial etiology.

Results: Of 111 patients with bacterial CAP, including 15 with severe CAP (as defined by the American Thoracic Society/Infectious Diseases Society of America criteria) and 63 with pneumococcal etiology, thrombomodulin was measured in plasma in all patients and in sputum in 42 patients. Elevated plasma thrombomodulin concentrations were independently associated with severe CAP. Stratification by bacterial etiology showed that higher plasma thrombomodulin concentrations were linked to severe pneumonia only in patients with pneumococcal infection. The area under the receiver operating characteristic curve for detecting severe pneumococcal CAP was 0.87. Conversely, sputum thrombomodulin concentrations showed no association with disease severity or bacterial etiology.

Conclusions: Plasma thrombomodulin is a promising biomarker for identifying severe pneumococcal CAP. Sputum thrombomodulin did not correlate with disease severity or bacterial etiology. These findings support further investigation into the diagnostic and prognostic role of plasma thrombomodulin in bacterial infections.

Place, publisher, year, edition, pages
Taylor & Francis, 2025
Keywords
Thrombomodulin, community-acquired pneumonia, Streptococcus pneumoniae, severe CAP, biomarker
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-122603 (URN)10.1080/23744235.2025.2528957 (DOI)001531033600001 ()40680037 (PubMedID)2-s2.0-105010922442 (Scopus ID)
Funder
Karolinska InstituteVinnova, 90456Swedish Research Council, 2018-151Swedish Research Council, 2022-01-202Region Stockholm
Note

Open access funding provided by Karolinska Institutet. The study was supported by grants from the Swedish Governmental Agency for Innovation Systems (VINNOVA) under the frame of NordForsk (90456), the Swedish Research Council under the frame of ERA PerMed (2018-151), the Swedish Research Council (to ANT, 2022-01-202) ,and Region Stockholm (ALF funding) and Center for Innovative Medicine to ANT.

Available from: 2025-07-31 Created: 2025-07-31 Last updated: 2026-01-23Bibliographically approved
Wahllöf, M., Hedlund, J., Lundqvist, A., Nilsson, A. C., Inghammar, M., Spindler, C., . . . Athlin, S. (2025). Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines. Infectious Diseases, 57(10), 979-1015
Open this publication in new window or tab >>Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines
Show others...
2025 (English)In: Infectious Diseases, ISSN 2374-4235, E-ISSN 2374-4243, Vol. 57, no 10, p. 979-1015Article in journal, Editorial material (Other academic) Published
Place, publisher, year, edition, pages
Taylor & Francis, 2025
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-123015 (URN)10.1080/23744235.2025.2543077 (DOI)001554961100001 ()40833837 (PubMedID)2-s2.0-105013775123 (Scopus ID)
Available from: 2025-08-25 Created: 2025-08-25 Last updated: 2026-01-23Bibliographically approved
Kättström, M., Uggla, B., Virta, C., Melin, M., Ekström, N., Magnuson, A., . . . Athlin, S. (2025). Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia. Haematologica, 110(8), 1774-1785
Open this publication in new window or tab >>Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia
Show others...
2025 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 110, no 8, p. 1774-1785Article in journal (Refereed) Published
Abstract [en]

Patients with chronic lymphocytic leukemia (CLL) have impaired response to vaccination, which calls for improved vaccination strategies. This study aimed to evaluate antibody persistence five years after pneumococcal vaccination and response to revaccination. Seventyfour CLL patients and 31 controls, all primary immunized with 13-valent conjugated pneumococcal vaccine (PCV13) or 23-valent polysaccharide vaccine (PPSV23), were included. Antibody persistence was assessed, followed by revaccination with PCV13 and a second revaccination with PCV13 or PPSV23. Serological protection (SP), defined as serum serotype specific IgG concentration ≥0.35 μg/mL for ≥70% of shared serotypes, did not differ significantly in CLL patients primary immunized with PCV13 or PPSV23 (RR 2.7 (95% CI 0.5-13.1)), but was lower in patients compared to controls (10% vs 32%; RR 0.3 (0.1-0.7)). Following revaccination with PCV13, serological response (SR), defined as ≥2-fold increase for ≥70% of shared serotypes, was 24% in patients primary immunized with PCV13 vs 12% with PPSV23 (RR 2.0 (0.6-6.9)). A second revaccination with PCV13 significantly improved SR while PPSV23 did not further improve immunity. Our findings suggest that repeated doses of a T-cell dependent pneumococcal vaccine improve protection in CLL patients. The study is registered at www.clinicaltrials.gov (NCT05316831).

Place, publisher, year, edition, pages
Ferrata Storti Foundation, 2025
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-119756 (URN)10.3324/haematol.2024.286942 (DOI)001547246400013 ()40045895 (PubMedID)2-s2.0-105013807290 (Scopus ID)
Funder
Region Örebro County, OLL-840421Region Örebro County, OLL-886921Region Örebro County, OLL-929805Region Örebro County, OLL-916971Nyckelfonden, OLL-890171Nyckelfonden, OLL-974753
Note

The study was supported by grants from Region Örebro County Research Committee (OLL-840421, OLL-886921, OLL-929805, OLL-916971) and Nyckelfonden (OLL-890171, OLL-974753), ALF funding in Region Örebro County and from Uppsala-Örebro Regional Research Council (RFR-930110, RFR-939461), Sweden.

Available from: 2025-03-07 Created: 2025-03-07 Last updated: 2026-01-23Bibliographically approved
Olsson, H., Tamire, M., Samuelsson, E., Addissie, A., Andersson, R., Skovbjerg, S. & Athlin, S. (2024). Household air pollution and pneumococcal density related to nasopharyngeal inflammation in mothers and children in Ethiopia: A cross-sectional study. PLOS ONE, 19(1), Article ID e0297085.
Open this publication in new window or tab >>Household air pollution and pneumococcal density related to nasopharyngeal inflammation in mothers and children in Ethiopia: A cross-sectional study
Show others...
2024 (English)In: PLOS ONE, E-ISSN 1932-6203, Vol. 19, no 1, article id e0297085Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Three billion people in low- and middle-income countries are exposed to household air pollution as they use biomass fuel for cooking. We investigated the associations between solid fuel use and nasopharyngeal (NP) inflammation, as well as the associations between high pneumococcal density and NP inflammation, in mothers and children in rural and urban Ethiopia.

MATERIALS AND METHODS: Sixty pairs of mothers (median age, 30 years; range, 19-45 years) with a child (median age, 9 months; range, 1-24 months) were included from rural Butajira (n = 30) and urban Addis Ababa (n = 30) in Ethiopia. The cohort was randomly selected from a previous study of 545 mother/child pairs included 2016. Questionnaire-based data were collected which included fuel type used (solid: wood, charcoal, dung or crop waste; cleaner: electricity, liquefied petroleum gas). Nasopharyngeal (NP) samples were collected from all mothers and children and analyzed for the levels of 18 cytokines using a Luminex immunoassay. Pneumococcal DNA densities were measured by a real-time multiplex PCR and a high pneumococcal density was defined as a cyclic threshold (Ct) value ≤ 30.

RESULTS: Mothers from rural areas had higher median CXCL8 levels in NP secretions than those from urban areas (8000 versus 1900 pg/mL; p < 0.01), while rural children had slightly higher IL-10 levels than those from the urban area (26 vs 13 pg/mL; p = 0.04). No associations between fuel type and cytokine levels were found. However, a high pneumococcal density was associated with higher levels of cytokines in both mothers (CCL4, CXCL8, IL-1β, IL-6 and VEGF-A) and children (CCL4, CXCL8, IL-1β, IL-6 and IL-18).

CONCLUSIONS: No significant associations were found between solid fuel use and NP inflammation in Ethiopian mothers and children, but the inflammatory activity was higher in individuals living in the rural compared to the urban area. In addition, high cytokine levels were associated with high pneumococcal density in both mothers and children, indicating a significant impact of NP pathogens on inflammatory mediator levels in upper airways.

Place, publisher, year, edition, pages
Public Library of Science (PLoS), 2024
National Category
Occupational Health and Environmental Health
Identifiers
urn:nbn:se:oru:diva-111224 (URN)10.1371/journal.pone.0297085 (DOI)001158471300096 ()38271409 (PubMedID)2-s2.0-85183480183 (Scopus ID)
Funder
Swedish Research Council, 2020-04653Region Örebro County, 807831
Available from: 2024-01-31 Created: 2024-01-31 Last updated: 2024-03-11Bibliographically approved
Kättström, M., Uggla, B., Tina, E., Kimby, E., Norén, T. & Athlin, S. (2023). Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia. Vaccine, 41(9), 3128-3136
Open this publication in new window or tab >>Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia
Show others...
2023 (English)In: Vaccine, ISSN 0264-410X, E-ISSN 1873-2518, Vol. 41, no 9, p. 3128-3136Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) show an immune dysfunction with increased risk of infections and poor response to vaccination. Streptococcus pneumoniae is a common cause of morbidity and mortality in CLL patients. In a previous randomized clinical trial, we found a superior immune response in CLL patients receiving conjugated pneumococcal vaccine compared to non-conjugated vaccine. The response to revaccination in CLL patients is scarcely studied. In this study, early humoral response to repeated revaccinations with pneumococcal vaccines was evaluated, by determination of B cell subsets and plasmablast dynamics in peripheral blood.

METHOD: CLL patients (n = 14) and immunocompetent controls (n = 31) were revaccinated with a 13-valent pneumococcal conjugate vaccine (PCV13) after previous primary immunization (3-6 years ago) with PCV13 or a 23-valent pneumococcal polysaccharide vaccine (PPSV23). Eight weeks after the first revaccination, all CLL patients received a second revaccination with PCV13 or PPSV23. B cell subsets including plasmablasts were analyzed in peripheral blood by flow cytometry, before and after the first and the second revaccination.

RESULTS: None of the CLL patients, but all controls, had detectable plasmablasts at baseline (p < 0.001). After the first revaccination with PCV13, the plasmablast proportions did not increase in CLL patients (p = 0.13), while increases were seen in controls (p < 0.001). However, after a second revaccination with PCV13 or PPSV23, plasmablasts increased compared to baseline also in CLL patients (p < 0.01). If no response was evident after first revaccination, only a second revaccination with PCV13 increased plasmablasts in contrast to PPSV23 revaccination. Patients with hypogammaglobulinemia and ongoing/previous CLL specific treatment responded poorly, also to a second revaccination.

CONCLUSION: In CLL patients, pneumococcal revaccination induced minor early plasmablast response compared to controls, but the response improved using a strategy of repeated doses with of conjugated T cell dependent pneumococcal vaccine.

Place, publisher, year, edition, pages
Elsevier, 2023
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-105539 (URN)10.1016/j.vaccine.2023.04.016 (DOI)000990402500001 ()37061372 (PubMedID)2-s2.0-85152584628 (Scopus ID)
Funder
Region Örebro CountyNyckelfonden
Note

Funding agency:

Uppsala-Örebro Regional Research Council

Available from: 2023-04-17 Created: 2023-04-17 Last updated: 2026-01-09Bibliographically approved
Brodin, D., Tornhammar, P., Ueda, P., Krifors, A., Westerlund, E., Athlin, S., . . . Andersson, D. P. (2023). Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19). BMJ Open, 13(2), Article ID e064374.
Open this publication in new window or tab >>Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19)
Show others...
2023 (English)In: BMJ Open, E-ISSN 2044-6055, Vol. 13, no 2, article id e064374Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To assess the efficacy of inhaled ciclesonide in reducing the duration of oxygen therapy (an indicator of time to clinical improvement) among adults hospitalised with COVID-19.

DESIGN: Multicentre, randomised, controlled, open-label trial.

SETTING: 9 hospitals (3 academic hospitals and 6 non-academic hospitals) in Sweden between 1 June 2020 and 17 May 2021.

PARTICIPANTS: Adults hospitalised with COVID-19 and receiving oxygen therapy.

INTERVENTION: Inhaled ciclesonide 320 µg two times a day for 14 days versus standard care.

MAIN OUTCOME MEASURES: Primary outcome was duration of oxygen therapy, an indicator of time to clinical improvement. Key secondary outcome was a composite of invasive mechanical ventilation/death.

RESULTS: Data from 98 participants were analysed (48 receiving ciclesonide and 50 receiving standard care; median (IQR) age, 59.5 (49-67) years; 67 (68%) men). Median (IQR) duration of oxygen therapy was 5.5 (3-9) days in the ciclesonide group and 4 (2-7) days in the standard care group (HR for termination of oxygen therapy 0.73 (95% CI 0.47 to 1.11), with the upper 95% CI being compatible with a 10% relative reduction in oxygen therapy duration, corresponding to a <1 day absolute reduction in a post-hoc calculation). Three participants in each group died/received invasive mechanical ventilation (HR 0.90 (95% CI 0.15 to 5.32)). The trial was discontinued early due to slow enrolment.

CONCLUSIONS: In patients hospitalised with COVID-19 receiving oxygen therapy, this trial ruled out, with 0.95 confidence, a treatment effect of ciclesonide corresponding to more than a 1 day reduction in duration of oxygen therapy. Ciclesonide is unlikely to improve this outcome meaningfully.

TRIAL REGISTRATION NUMBER: NCT04381364.

Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2023
Keywords
COVID-19, clinical trials, respiratory infections
National Category
Anesthesiology and Intensive Care Cardiology and Cardiovascular Disease
Identifiers
urn:nbn:se:oru:diva-104438 (URN)10.1136/bmjopen-2022-064374 (DOI)000944467100011 ()36813503 (PubMedID)2-s2.0-85148548652 (Scopus ID)
Available from: 2023-02-23 Created: 2023-02-23 Last updated: 2025-02-10Bibliographically approved
Shine, S., Tamirie, M., Kumie, A., Addissie, A., Athlin, S., Mekonnen, H., . . . Kaba, M. (2023). Pregnant women's perception on the health effects of household air pollution in Rural Butajira, Ethiopia: a phenomenological qualitative study. BMC Public Health, 23(1), Article ID 1636.
Open this publication in new window or tab >>Pregnant women's perception on the health effects of household air pollution in Rural Butajira, Ethiopia: a phenomenological qualitative study
Show others...
2023 (English)In: BMC Public Health, E-ISSN 1471-2458, Vol. 23, no 1, article id 1636Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Household air pollution is the major public health problem in developing countries. Pregnant women spent the majority of their time at home and are the most affected population by household air pollution. Exploring the perception of pregnant women on adverse health effects is important to enhance the mitigation strategies. Therefore, this study aim to explore the pregnant women's perceptions about health effects of household air pollution in rural Butajira, Ethiopia.

METHODS: A phenomenological qualitative study design was conducted among 15 selected pregnant women. All interviews were carried out at the participants´ house and audio-recorded while housing and cooking conditions were observed and appropriate notes were taken for each. The collected data were transcribed verbatim and translated into the English language. Then, the data were imported into Open code software to manage the overall data coding processes and analyzed thematically.

RESULTS: Study participants perceived that respiratory problems such as coughing, sneezing and asthma and eye problem were the major health problem caused by household air pollution among pregnant women. Study participants also mentioned asphyxiated, abortion, reduces weight, and hydrocephalus was caused by household air pollution on the foetus. Study participants perceived that financial inability, spouse negligence, autonomy and knowledge level of the women were the barriers to tackling household air pollution. Study participant also suggested that opening the door and window; using improved cookstove and reduce workload were the perceived solution for household air pollution.

CONCLUSIONS: This study explores pregnant women's perceptions on health effects of household air pollution. The finding of this study was important to deliver suitable intervention strategies to mitigate household air pollution. Therefore, educating the women on way of mitigating household air pollution, improving existing structure of the house and minimize the time to stay in the kitchen is important to mitigate household air pollution exposure.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2023
Keywords
Butajira, Ethiopia, Household air pollution, Pregnant mother perception, Qualitative study
National Category
Public Health, Global Health and Social Medicine
Identifiers
urn:nbn:se:oru:diva-107862 (URN)10.1186/s12889-023-16578-8 (DOI)001054758500004 ()37626318 (PubMedID)2-s2.0-85168720429 (Scopus ID)
Note

Funding agency:

Addis Ababa University

Available from: 2023-08-28 Created: 2023-08-28 Last updated: 2025-02-20Bibliographically approved
Hammarström, H., Krifors, A., Athlin, S., Friman, V., Golestani, K., Hällgren, A., . . . Blennow, O. (2023). Treatment with reduced dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with hematologic malignancies. Clinical Infectious Diseases, 76(3), e1252-e1260
Open this publication in new window or tab >>Treatment with reduced dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with hematologic malignancies
Show others...
2023 (English)In: Clinical Infectious Diseases, ISSN 1058-4838, E-ISSN 1537-6591, Vol. 76, no 3, p. e1252-e1260Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Recent studies have reported that reduced dose trimethoprim-sulfamethoxazole (TMP-SMX) may be effective in the treatment of Pneumocystis jirovecii pneumonia (PJP) but data is lacking for patients with hematologic malignancies.

METHODS: This retrospective study included all adult hematologic patients with PJP between 2013 and 2017 at six Swedish University Hospitals. Treatment with 7.5-15 mg TMP/kg/day (reduced dose) was compared with >15-20 mg TMP/kg/day (standard dose), after correction for renal function. The primary outcome was the change in respiratory function (ΔPaO2/FiO2) between baseline and day 8. Secondary outcomes were clinical failure and/or death at day 8 and death at day 30.

RESULTS: Out of a total of 113 included patients, 80 patients received reduced dose, and 33 patients received standard dose. The overall 30-day mortality in the whole cohort was 14%. There were no clinically relevant differences in ΔPaO2/FiO2 at day 8 between the treatment groups, neither before nor after controlling for potential confounders in an adjusted regression model (-13,6 mmHg [95% CI -56,7-29,5] and -9,4 mmHg, [95% CI -50.5-31.7], respectively). Clinical failure and/or death at day 8 and 30-day mortality did not differ significantly between the groups, 18% vs. 21% and 14% vs. 15%, respectively. Among patients with mild to moderate pneumonia, defined as PaO2/FiO2>200 mmHg, all 44 patients receiving reduced dose were alive at day 30.

CONCLUSION: In this cohort of 113 patients with hematologic malignancies, reduced dose TMP-SMX was effective and safe for treating mild to moderate PJP.

Place, publisher, year, edition, pages
University of Chicago Press, 2023
Keywords
Pneumocystis pneumonia, Hematologic malignancies, Treatment Outcome, trimethoprim-sulfamethoxazole
National Category
Infectious Medicine
Identifiers
urn:nbn:se:oru:diva-99105 (URN)10.1093/cid/ciac386 (DOI)000819031800001 ()35594562 (PubMedID)2-s2.0-85147783441 (Scopus ID)
Note

Funding agencies:

Swedish National Health Services through Örebro University

National Health Services

Available from: 2022-05-23 Created: 2022-05-23 Last updated: 2023-03-15Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-8730-6955

Search in DiVA

Show all publications